Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
1745
mi
from 91732
Green Bay, WI
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1745
mi
from 91732
Green Bay, WI
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
1727
mi
from 91732
Kenosha, WI
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1727
mi
from 91732
Kenosha, WI
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
1654
mi
from 91732
Madison, WI
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
6113
mi
from 91732
Buenos Aires,
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Merck Sharp & Dohme (Argentina) Inc.
6113
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
2570
mi
from 91732
Methuen, MA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2570
mi
from 91732
Methuen, MA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
1564
mi
from 91732
Hazelwood, MO
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1564
mi
from 91732
Hazelwood, MO
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
2439
mi
from 91732
Hopewell Junction, NY
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2439
mi
from 91732
Hopewell Junction, NY
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
2429
mi
from 91732
New Windsor, NY
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2429
mi
from 91732
New Windsor, NY
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
2174
mi
from 91732
Moncks Corner, SC
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2174
mi
from 91732
Moncks Corner, SC
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
1978
mi
from 91732
Macon, GA
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1978
mi
from 91732
Macon, GA
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
1223
mi
from 91732
Desoto, TX
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1223
mi
from 91732
Desoto, TX
Click here to add this to my saved trials
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated:  12/31/1969
2214
mi
from 91732
Raleigh, NC
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2214
mi
from 91732
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
825
mi
from 91732
Aurora, CO
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Barbara Davis Center for Diabetes
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
827
mi
from 91732
Portland, OR
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
1791
mi
from 91732
Indianapolis, IN
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children at Indiana University Health
1791
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
2104
mi
from 91732
Gainesville, FL
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Florida
2104
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
1511
mi
from 91732
Minneapolis, MN
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 91732
Philadelphia, PA
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
2181
mi
from 91732
Buffalo, NY
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
UPA Buffalo
2181
mi
from 91732
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated:  12/31/1969
2486
mi
from 91732
New Haven, CT
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Efficacy and Safety of Nasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes
Status: Enrolling
Updated: 12/31/1969
Yale University
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
825
mi
from 91732
Aurora, CO
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Barbara Davis Center for Diabetes
825
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
2130
mi
from 91732
Jacksonville, FL
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic
2130
mi
from 91732
Jacksonville, FL
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
1791
mi
from 91732
Indianapolis, IN
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children at Indiana University Health
1791
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
2104
mi
from 91732
Gainesville, FL
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
University of Florida
2104
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
1511
mi
from 91732
Minneapolis, MN
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
2181
mi
from 91732
Buffalo, NY
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
UPA Buffalo
2181
mi
from 91732
Buffalo, NY
Click here to add this to my saved trials
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
2486
mi
from 91732
New Haven, CT
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Yale University
2486
mi
from 91732
New Haven, CT
Click here to add this to my saved trials
Examination of the Pancreas in New-onset Diabetes
Examination of the Pancreas in New-onset Diabetes (EXPAND Study)
Status: Enrolling
Updated:  12/31/1969
1524
mi
from 91732
Rochester, MN
Examination of the Pancreas in New-onset Diabetes
Examination of the Pancreas in New-onset Diabetes (EXPAND Study)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
The Use of Glutamic Acid Decarboxylase (GAD)and Gamma-Amino Butyric Acid(GABA)in the Treatment of Type I Diabetes.
Status: Enrolling
Updated:  12/31/1969
1784
mi
from 91732
Birmingham, AL
The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes
The Use of Glutamic Acid Decarboxylase (GAD)and Gamma-Amino Butyric Acid(GABA)in the Treatment of Type I Diabetes.
Status: Enrolling
Updated: 12/31/1969
Children's of Alabama
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1459
mi
from 91732
Little Rock, AR
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Medical Investigations, Inc.
1459
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
84
mi
from 91732
Escondido, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
AMCR Institute, Inc
84
mi
from 91732
Escondido, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
216
mi
from 91732
Fresno, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Valley Research
216
mi
from 91732
Fresno, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
366
mi
from 91732
Sacramento, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Center of Excellence in Diabetes & Endocrinology
366
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
24
mi
from 91732
Torrance, CA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
So Cal Diabetes
24
mi
from 91732
Torrance, CA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
2182
mi
from 91732
Lake Mary, FL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Endocrine Associates of Florida, P.A.
2182
mi
from 91732
Lake Mary, FL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
2219
mi
from 91732
Naples, FL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
TLC Diabetes Healthcare Consultants & Education Inc.
2219
mi
from 91732
Naples, FL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
2133
mi
from 91732
Tampa, FL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Pediatric Endocrine Associates
2133
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1918
mi
from 91732
Atlanta, GA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Atlanta Diabetes Associates
1918
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1909
mi
from 91732
Columbus, GA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
East Alabama Endocrinology PC
1909
mi
from 91732
Columbus, GA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1917
mi
from 91732
Roswell, GA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Endocrine Research Solutions, Inc.
1917
mi
from 91732
Roswell, GA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1730
mi
from 91732
Chicago, IL
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
University of Chicago
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1725
mi
from 91732
Terre Haute, IN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Isaiah Pittman IV, MD
1725
mi
from 91732
Terre Haute, IN
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1717
mi
from 91732
Vincennes, IN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital Physician Services
1717
mi
from 91732
Vincennes, IN
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1422
mi
from 91732
Des Moines, IA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Iowa Diabetes and Endocrinology Center
1422
mi
from 91732
Des Moines, IA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1471
mi
from 91732
Lake Charles, LA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Imperial Health
1471
mi
from 91732
Lake Charles, LA
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
2361
mi
from 91732
Salisbury, MD
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Eastern Shore Diabetes and Endocrinology Center
2361
mi
from 91732
Salisbury, MD
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1958
mi
from 91732
Bloomfield Hills, MI
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Grunberger Diabetes Institute
1958
mi
from 91732
Bloomfield Hills, MI
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1841
mi
from 91732
Grand Rapids, MI
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
Spectrum Health System
1841
mi
from 91732
Grand Rapids, MI
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1505
mi
from 91732
Minneapolis, MN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
International Diabetes Center
1505
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated:  12/31/1969
1524
mi
from 91732
Rochester, MN
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials